Every 10-Q that Quince (QNCX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QNCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNCX filings page.
Quince Therapeutics, Inc. reports second-quarter 2026 results reflecting a major strategic shift and complex capital actions. The company abandoned its prior eDSP program after a Phase 3 failure, recording a $67.8 million intangible impairment and eliminating related contingent consideration liabilities of $64.3 million.
In May 2026 Quince completed the asset acquisition of Orphai, obtaining lead asset LAM-001 and recording $59.0 million of acquired in-process R&D expense and a $1.3 million gain on acquisition. Concurrently, it raised $115.0 million gross via a private placement of Series C non-voting convertible preferred stock and warrants, plus $20.3 million net through an ATM program, and settled its EIB debt for $5.5 million, removing $18.0 million of debt from the balance sheet.
Cash and cash equivalents rose to $116.0 million at June 30, 2026, but the Series C Preferred Stock’s potential cash-settlement feature means these proceeds cannot fully alleviate liquidity risk. With an accumulated deficit of $500.0 million and a six-month net loss of $39.6 million, management concludes that substantial doubt about continuing as a going concern exists over the next year.
Quince Therapeutics reported a sharp swing to profitability for the three months ended March 31, 2026, with net income of $35.9 million versus a $15.0 million loss a year earlier. The profit was driven mainly by non-cash fair value gains on contingent consideration, warrants, and debt.
The company’s Phase 3 NEAT trial of its lead asset eDSP in A-T failed to meet primary and secondary endpoints, and Quince has ceased development of eDSP in all indications. This triggered a $67.8 million impairment of intangible assets and the elimination of up to $485.0 million in potential contingent payments from the EryDel acquisition.
Cash and cash equivalents were $18.2 million as of March 31, 2026, supported by $15.0 million of net proceeds from at-the-market share sales and settlement of the EIB loan for approximately $5.5 million. Management states that existing cash is not sufficient to fund at least 12 months of operations, concluding that substantial doubt exists about Quince’s ability to continue as a going concern while it pursues strategic alternatives and restructuring.
Quince Therapeutics reported third‑quarter results and disclosed “substantial doubt” about its ability to continue as a going concern. The company posted a Q3 net loss of $13.4 million and a nine‑month net loss of $44.5 million.
Cash, cash equivalents, and short‑term investments were $26.3 million as of September 30, 2025. Quince raised additional capital through an ATM program (net $4.3 million YTD) and a June 2025 private placement that issued common stock, pre‑funded warrants, and common warrants for gross proceeds of $11.5 million.
The balance sheet shows a $17.5 million current portion of the EIB loan (fair value) due August 2026, $61.2 million in long‑term contingent consideration tied to the EryDel acquisition, and $14.9 million warrant liabilities. Stockholders’ equity was $1.1 million. Shares outstanding were 55,681,490 as of November 6, 2025.
Quince Therapeutics is a late-stage biotech developing the AIDE red blood cell encapsulation platform and a Phase 3 lead asset, eDSP, targeting Ataxia-Telangiectasia. The company reported consolidated assets of $117.2 million, liabilities of $105.5 million, and stockholders' equity of $11.7 million as of June 30, 2025. Cash, cash equivalents and short-term investments totaled $34.7 million, while the accumulated deficit was $407.6 million.
Operating results show a continuing loss: $16.0 million net loss for the quarter and $31.1 million for the six months ended June 30, 2025, driven by higher R&D spending ($14.7 million for six months) and other non-cash fair value adjustments. The balance sheet includes €10.0 million ($11.7M) outstanding on an EIB loan, contingent consideration of $59.1 million, and warrant liabilities of $15.1 million. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern within one year and notes the need for additional financing despite recent capital raises totaling approximately $14.4 million from a June 2025 private placement and ATM activity.